BRPI0410635A - isÈmeros enriquecidos e opticamente puros de ligantes de quelação e agentes de contraste - Google Patents

isÈmeros enriquecidos e opticamente puros de ligantes de quelação e agentes de contraste

Info

Publication number
BRPI0410635A
BRPI0410635A BRPI0410635-0A BRPI0410635A BRPI0410635A BR PI0410635 A BRPI0410635 A BR PI0410635A BR PI0410635 A BRPI0410635 A BR PI0410635A BR PI0410635 A BRPI0410635 A BR PI0410635A
Authority
BR
Brazil
Prior art keywords
optically pure
contrast agents
binders
chelation
enriched isomers
Prior art date
Application number
BRPI0410635-0A
Other languages
English (en)
Inventor
John C Amedio
Peter D Caravan
Vincent Jacques
Kevin L Zhou
Stuart Levy
Shirley Kalogeropoulos
Matthew Greenfield
Original Assignee
Epix Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epix Pharm Inc filed Critical Epix Pharm Inc
Publication of BRPI0410635A publication Critical patent/BRPI0410635A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"ISÈMEROS ENRIQUECIDOS E OPTICAMENTE PUROS DE LIGANTES DE QUELAçãO E AGENTES DE CONTRASTE". A presente invenção refere-se a ligantes orgânicos de quelação, precursores de ligante de quelação e quelatos de metal. Processos para sintetização dos mesmos são também descritos, incluindo processos para preparação de composições opticamente puras ou opticamente enriquecidas dos mesmos.
BRPI0410635-0A 2003-05-23 2004-05-20 isÈmeros enriquecidos e opticamente puros de ligantes de quelação e agentes de contraste BRPI0410635A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47336903P 2003-05-23 2003-05-23
PCT/US2004/016029 WO2005001415A2 (en) 2003-05-23 2004-05-20 Optically pure and enriched isomers of chelating ligands and contrast agents

Publications (1)

Publication Number Publication Date
BRPI0410635A true BRPI0410635A (pt) 2006-06-13

Family

ID=33551444

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410635-0A BRPI0410635A (pt) 2003-05-23 2004-05-20 isÈmeros enriquecidos e opticamente puros de ligantes de quelação e agentes de contraste

Country Status (6)

Country Link
US (2) US20060155120A1 (pt)
EP (1) EP1641495A4 (pt)
CN (1) CN1795015A (pt)
BR (1) BRPI0410635A (pt)
CA (1) CA2526760A1 (pt)
WO (1) WO2005001415A2 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2891830B1 (fr) 2005-10-07 2011-06-24 Guerbet Sa Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale
GB0624587D0 (en) * 2006-12-08 2007-01-17 Univ Muenchen Tech Chelating agent
AU2009204427B2 (en) * 2008-01-08 2013-10-03 Lantheus Medical Imaging, Inc. N-alkoxyamide conjugates as imaging agents
CN102272109A (zh) * 2008-11-11 2011-12-07 南洋理工大学 血管内造影剂
WO2010108063A1 (en) * 2009-03-19 2010-09-23 Wyeth Llc Methods for the preparation of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)ethyl]phosphonic acid and precursors thereof
WO2010121133A2 (en) * 2009-04-17 2010-10-21 The General Hospital Corporation Multimodal imaging of fibrin
JP5676600B2 (ja) 2009-07-08 2015-02-25 ランセウス メディカル イメージング， インコーポレイテッド 造影剤としてのｎ−アルコキシアミド抱合体
US20170050989A1 (en) * 2013-12-03 2017-02-23 The General Hospital Corporation Molecular Imaging Probes
EP3015462A1 (en) 2014-10-29 2016-05-04 OctreoPharm Schiences GmbH Enantiopure chelating agents for chelator coupled pharmaceuticals, corresponding preparation method thereof and chelator coupled pharmaceuticals
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
US11357873B2 (en) 2016-09-19 2022-06-14 The Hong Kong Polytechnic University Chiral cyclen compounds and their uses
CN110035996B (zh) 2016-11-28 2022-08-09 拜耳医药股份公司 用于磁共振成像的新型高弛豫性钆螯合物
EP3638320A4 (en) 2017-05-05 2021-01-20 Centre for Probe Development and Commercialization IGF-1R MONOCLONAL ANTIBODIES AND USES THEREOF
US10093741B1 (en) 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof
WO2018204869A1 (en) 2017-05-05 2018-11-08 Fusion Pharmaceuticals Inc. Pharmacokinetic enhancements of bifunctional chelates and uses thereof
EP3883613A1 (en) 2018-11-23 2021-09-29 Bayer Aktiengesellschaft Formulation of contrast media and process of preparation thereof
CN110286168B (zh) * 2019-07-03 2023-03-03 浙江普利药业有限公司 显影剂中多氨基多羧基化合物的测定方法
KR20220104703A (ko) * 2019-10-23 2022-07-26 콜라겐 메디컬, 엘엘씨 영상화 및 치료용 피브린-결합 화합물
BR112023000763A2 (pt) * 2020-07-13 2023-03-21 Point Biopharma Inc Composição farmacêutica, método para preparar 177lu-psma i&t, método para tratar um paciente, complexo, método para tratar um indivíduo
CN114181164A (zh) * 2021-12-13 2022-03-15 武汉大学中南医院 基于Fe(Ⅱ)特异性MRI对比剂的合成方法及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4899755A (en) * 1985-05-08 1990-02-13 The General Hospital Corporation Hepatobiliary NMR contrast agents
US4880008A (en) * 1985-05-08 1989-11-14 The General Hospital Corporation Vivo enhancement of NMR relaxivity
TW319763B (pt) 1995-02-01 1997-11-11 Epix Medical Inc
AU768957B2 (en) * 1999-02-18 2004-01-08 Regents Of The University Of California, The Phthalamide-lanthanide complexes for use as luminescent markers
DK1154991T3 (da) * 1999-02-18 2004-11-22 Univ California Salicylamid-lanthanidkomplekser til anvendelse som luminescerende markörer
WO2001009188A1 (en) 1999-07-29 2001-02-08 Dyax Corp. Binding moieties for fibrin
PL353336A1 (en) 1999-07-29 2003-11-17 Epix Medical, Inc. Targeting multimeric imaging agents through multilocus binding
ES2221903T3 (es) * 2000-05-12 2005-01-16 University Hospital Agentes pro-quelantes para la preparacion de moleculas marcadas con metales radiactivos que tienen propiedades biologicas mejoradas.
US6549798B2 (en) * 2001-02-07 2003-04-15 Epix Medical, Inc. Magnetic resonance angiography data

Also Published As

Publication number Publication date
EP1641495A2 (en) 2006-04-05
WO2005001415A2 (en) 2005-01-06
WO2005001415A3 (en) 2005-07-21
US8048906B2 (en) 2011-11-01
CA2526760A1 (en) 2005-01-06
US20070244316A1 (en) 2007-10-18
CN1795015A (zh) 2006-06-28
EP1641495A4 (en) 2009-02-25
US20060155120A1 (en) 2006-07-13

Similar Documents

Publication Publication Date Title
BRPI0410635A (pt) isÈmeros enriquecidos e opticamente puros de ligantes de quelação e agentes de contraste
BRPI0607455A2 (pt) composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica
WO2007106192A3 (en) Inhibitors of iap
ATE433447T1 (de) Pyrimiidinverbindungen
GEP20074133B (en) New process for the synthesis and new crystalline form of agomelatine and pharmaceutical compositions containing it
MXPA04004464A (es) Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades.
BR0308261A (pt) Métodos extrativos para puruficação de sucralose
MXPA02012425A (es) Compuestos nuevos.
MXPA02011370A (es) Iminoazinas substituidas.
ZA200702700B (en) Diagnostic compounds
BR9713925A (pt) Composto, processo para preparação de um composto, e, composição farmacêutica
BRPI0417543A (pt) quinolinas úteis no tratamento de doença cardiovascular
MY136800A (en) Inhibitors of the interaction between mdm2 and p53
MXPA04000210A (es) Conjugados quelantes mejorados.
MXPA05012268A (es) N-arilsulfonilpiperidinas enlazadas como inhibidores de la gamma-secretasa.
EA200801025A1 (ru) Композиция и синтез новых реагентов для ингибирования репликации вич
MXPA05012837A (es) Inhibidores de caspasa y usos de los mismos.
SE0403171D0 (sv) New compounds
ATE291024T1 (de) Neue 4-aminofuropyrimidine und ihre verwendung
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
CR9182A (es) Derivado de quinolina, su uso, preparacion y medicamento que lo contiene
ATE432074T1 (de) Sulfhydantoine als phosphatisostere zur verwendung als phosphatasehemmer bei der behandlung von krebs und autoimmunerkrankungen
MXPA04006266A (es) Pirimidotriazinas como inhibidores de fosfatasa.
MXPA04002282A (es) Nuevos compuestos y preparaciones como inhibidores de la catepsina.
BRPI0506477A (pt) compostos farmaceuticamente úteis e inovadores

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL